All posts by imreal

Dr. Sergio Yero & Dr. Wilbert D. Yeung of Advanced Psychiatric Associates Named NJ Top Docs


News Image

NJ Top Docs has reviewed and approved Sergio Yero, MD, FAPA and Wilbert D. Yeung, MD of Advanced Psychiatric Associates as top doctors in the field of Psychiatry for 2022. Advanced Psychiatric Associates is a behavioral health group practice dedicated to providing the best possible care in a relaxed, comfortable private office setting.

They currently have three convenient locations in Hackensack, Glen Rock, and Florham Park.

Drs. Yero and Yeung treat children, adolescents, adults, and families with a variety of conditions including anxiety, depression, OCD, addiction, mood disorders, ADHD, and behavioral issues.

They provide a full range of therapies including Cognitive Behavioral Therapy, Couples and Family Therapy, FBT for Eating Disorders, Parent Guidance and Consultation, Psychodynamic Psychotherapy, Psychopharmacology, Suboxone Induction and Maintenance, and Supportive Psychotherapy.

Dr. Sergio Yero is Board Certified in both General Psychiatry and Addiction Psychiatry. His areas of expertise are psychopharmacology, addiction psychiatry, refractory psychiatric illnesses, personality and mood disorders.

To learn more about Dr. Yero, please visit: https://njtopdocs.com/nj-doctors/dr-sergio-yero/

Dr. Wilbert Yeung is Board Certified in General Psychiatry and Child & Adolescent Psychiatry. He is experienced in treating a wide range of conditions including mood disorders, depression, anxiety, OCD, ADHD, behavioral issues, and eating disorders. He completed a Triple Board Residency in Pediatrics, Psychiatry, Child and Adolescent Psychiatry at Brown University, where he was an Assistant Instructor and Chief Resident.

To learn more about Dr. Yeung, please visit: https://njtopdocs.com/nj-doctors/wilbertyeungmd/

—

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy-to-use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



A Book Of Poetry” is an engaging collection of personal poetry that motivates and inspires


News Image

“Disguised Blessings: A Book Of Poetry”: an enjoyable selection of poetry. “Disguised Blessings: A Book Of Poetry” is the creation of published author Orpha Ale Mineque, a registered nurse who worked for one of the Veteran Affairs(VA) Medical Centers in Florida where she worked until February 2022. She has spent her nursing career in the intensive care unit since she graduated from the Philippine Union College, in Silang, Cavite, Philippines, in 1985, which is now the Adventist University of the Philippines. Mineque migrated to the United States in April 1987 and took a job in the step-down surgical intensive care unit at Detroit Receiving Hospital and Trauma Center in Detroit, Michigan, until November 1988. She joined her family in Saint Petersburg, Florida, and started working at Palms of Pasadena Hospital in 1988 until 2000. She later relocated to Palo Alto in February 2022 where she currently works. In November 2000, Mineque became the co-owner and administrator for Duey’s Place Assisted Living Facility, a six-bed long-term-care facility that she and her husband, Napoleon Duey, operated together.

Mineque shares, “Disguised Blessings is a book of poetry. This is a compilation of poems that I wrote for about a year when the COVID-9 pandemic started in 2020.

“The poems will take your imagination to stories of my personal life, friends, and families. They were the people who inspired me and played vital roles in my life. It will also take you back to my youth and the island I grew up in. In my poems I also shared stories of how wonderful it is to love, be loved, and the hurtful experience of being rejected.

“A lot of the poetry I wrote were inspired by nature and its beauty that surrounds me. I saw God’s glory through His creation and heard His voice and felt His presence.

“Disguised Blessings are my unexpected gifts that I personally received amid the pandemic. Being a registered nurse working in the frontline is unnerving. God had protected and shielded me from COVID-19 so I could continue serving in His ministry of healing.

“God had blessed me with talents that I was able to use when I most needed them to keep myself above all chaos from the pandemic. I was able to do many projects to maintain a healthy mind and spirit. Best of all, He endowed me with special and beautiful thoughts that flowed into rhythmic words of poetry.

“I’m inviting you to emerge into the pages of this book and be inspired!”

Published by Christian Faith Publishing, Orpha Ale Mineque’s new book will entertain and encourage as readers reflect on the carefully designed verses within.

Mineque shares in celebration of life’s peaks and valleys as she recounts key moments within her life through her expressive poetic works.

Consumers can purchase “Disguised Blessings: A Book Of Poetry” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Disguised Blessings: A Book Of Poetry,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

SIUE School of Nursing Gains $4M HRSA Grant to Launch Mobile Health Unit and Training Enhancement Program


(L-R) Jerrica Ampadu, PhD, RN, CCP, associate professor, Amelia Perez, PhD, RN, associate professor, Rebecca Luebbert, PhD, PMHCNS-BC, professor, and Melissa Bogle, DNP, APRN, MPH, assistant professor

We are focused on promoting health equity by increasing access to care, growing the number of students who are prepared to address the social determinants of health within the community setting and training more underrepresented students in community health.

Southern Illinois University Edwardsville’s School of Nursing (SON) has received its largest grant in history— $4 million from the Health Resources and Services Administration (HRSA) — to develop a mobile health unit that will provide community-based services in East St. Louis, Fairmont City, and surrounding communities.

“We are focused on promoting health equity by increasing access to care, growing the number of students who are prepared to address the social determinants of health within the community setting and training more underrepresented students in community health,” said Principal Investigator (PI) Jerrica Ampadu, PhD, RN, CCP, associate professor, and director of the SIUE SON’s WE CARE Clinic in East St. Louis.

The four-year project is entitled, “Nurse education, practice, quality, and retention-mobile health training program – WE CARE REACH: Responding, educating, and advocating for community health.”

The mobile health unit, WE CARE REACH, will offer primary care and chronic care management services. It will be staffed by an interprofessional team of healthcare providers, including nurse practitioners, undergraduate and graduate nursing students, a social worker, a nutritionist and a pharmacist.

Co-PIs include the SON’s Amelia Perez, PhD, RN, associate professor, Rebecca Luebbert, PhD, PMHCNS-BC, professor, and Melissa Bogle, DNP, APRN, MPH, assistant professor. The team will design curriculum to enhance SIUE’s student training in underserved population groups during the creation of the new mobile health clinic. The project team will also engage in community outreach and education about the profession of nursing and recruit K-12 students into nursing.

“To educate nursing students on the social determinants of health, which include how racism impacts nursing and the deliverer of healthcare, students will participate in a Community Nurse Fellowship,” shared Ampadu. “Students will be immersed in community health for over 100 clinical hours learning with the interprofessional team and addressing health disparities.”

In addition to funding the mobile health unit, the HRSA grant provides undergraduate nursing students with $1,000 stipends to help increase their interest and ability to join the nursing workforce within underserved primary care settings.

The SON hopes the mobile unit will begin services in summer of 2023.

The School of Nursing’s programs are committed to creating excellence in nursing leadership through innovative teaching, evidence-based practice, quality research, patient advocacy and community service. Enrolling more than 1,700 students in its baccalaureate, master’s and doctoral programs, the School develops leaders in pursuit of shaping the nursing profession and impacting the health care environment. SIUE’s undergraduate nursing programs on the Edwardsville campus help to solve the region’s shortage of baccalaureate-prepared nurses and enhance the quality of nursing practice within all patient service venues. The School’s graduate programs prepare nurses for advanced roles in clinical practice, administration and education.

Share article on social media or email:

Volume 4” is a powerful testimony of faith and the real world


News Image

“Heaven Is Closer Than You Think: Love Letters to the World: Volume 4”: an uplifting message of God’s promise. “Heaven Is Closer Than You Think: Love Letters to the World: Volume 4” is the creation of published author Fred Blom.

Blom shares, “this is a testimony of real life, not games or movies. The majority of the people in the world don’t believe in the one and only God. Then there are fewer who believe in Jesus Christ. Of that group, how many drift in and out of this commitment? How many worship with their lips, but not their hearts? My parents and relatives fell into the group of ‘there is no God, just nature and the natural renewal of its cycle.’ For me, curiosity was the thing. I had to know the beginning and end of everything step-by-step. It’s the way I am built! I want every breath and every step I take to take me closer to Jesus Christ. Walk with me, and we will see how close heaven really is to us. Run away with me, and I bet we will run right into the hand of God. I have done it a couple of times! I want you to come with me! Please, it’s important!

“Why write this testimony of life? Did I say, ‘Please, come along with me’? Well, we all have the happy and sad, the hard and easy, and the close to God, whether we are aware of it or not, and the far from God, which we do not understand. Just a few weeks ago, I asked my Father in heaven if I should continue to write the first testimonials each month or perhaps even reveal the deep things that have helped me through life. In the process and time of seven days, I was shown how the hidden secrets of heaven work. To me, it’s funny, serious, and truthful—this simple thing connecting so many things together that have occurred in my life.

“I work on my testimonial stories at night. It was the hand of God that led me to do that, no doubt, and you will learn that a little later. There are always more people to give them to than I can accomplish.

“‘Maybe I should put them in a book for everyone, Father. I don’t have the time or know-how…’ I felt something like a tap on the back of my head when I prayed that. I slapped my hand over my mouth, trying to take it back; at the same time, I looked behind myself to see if something had fallen off the wall. I stopped praying, took a big sigh, and went to sleep. Why did I say ‘too busy’? I wrestled all night with ‘The secrets of heaven are my Lord Jesus Christ’s, but that which he gives us are ours.’

“For there is nothing covered that shall not be revealed; neither hid, that shall not be known. (Luke 12:2)

“I was referred to recently as the little lion that would not roar and the lost generation. Then a voice stood up for me and said, ‘No, this is the one who walks the dusty road.’

“I wanted to respond, but I fell to the ground in weakness because of the awesomeness around me. I was shown the loss of mankind and told to go forth with the testimony I was given. I cry and pray with great supplication before the heavenly throne of our savior, Jesus Christ. I don’t want anyone to be lost!

“Love in Christ,

Fred”

Published by Christian Faith Publishing, Fred Blom’s new book presents readers with an impactful opportunity for reflection and spiritual growth.

Blom shares in hopes of aiding others along their journey to a fulfilling connection with God.

Consumers can purchase “Heaven Is Closer Than You Think: Love Letters to the World: Volume 4” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Heaven Is Closer Than You Think: Love Letters to the World: Volume 4,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Elouise H. Hults’s newly released “Ordinary Reflections from Here, There, and God’s Word” is an uplifting devotional that will encourage all year long


News Image

“Ordinary Reflections from Here, There, and God’s Word”: an encouraging arrangement of thoughtful devotions. “Ordinary Reflections from Here, There, and God’s Word” is the creation of published author Elouise H. Hults, a loving wife, mother, grandmother, and great-grandmother.

Hults shares, “In our daily routine, God often places responses and directions for us in ways we believe provide needed answers for whatever that is or will be there for us to deal with. Those very words heard or read are often from something or someone nearby, during our personal and regular activities or situation, sharing needed encouragement, direction, or some type of help for any future issue that may arrive. And yes, of course, God does provide answers with direction or loving blessings specifically for us straight from His Word.

“Take time in each daily reading of Ordinary Reflections from Here, There, and God’s Word to reflect on them. Each one comes from the basic and ordinariness that’s all around us, or even straight from one’s own life, as well as from the Bible. This book includes a scripture verse beginning each day’s reading and then concludes with a brief prayer. Do be blessed as you read, meditate, and receive what the Lord has for you.”

Published by Christian Faith Publishing, Elouise H. Hults’s new book will engage the spirit and inspire the soul as readers ruminate with God’s word.

Hults shares in hopes of helping others live fulfilled lives through careful study and appreciation of all God has to offer.

Consumers can purchase “Ordinary Reflections from Here, There, and God’s Word” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Ordinary Reflections from Here, There, and God’s Word,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

WCG FDAnews Announces the Clinical Trials Track at the 17th Annual FDA Inspections Summit, Nov. 16-18, 2022, Washington, DC


17th Annual FDA Inspections Summit

**Presented by WCG FDAnews**

Nov. 16-18, 2022 • Washington, DC

Inspections Summit (11/16-18) Clinical Trials Track

https://wcg.swoogo.com/fda-inspections-summit-2022

The Clinical Trials track at the 17th Annual FDA Inspections Summit has been carefully crafted to provide everything clinical trials professionals need to ensure inspection success.

FDA and clinical trial industry VIPs will lead every session and workshop will help attendees pass future inspections, no matter their current challenges.

The event begins with Elizabeth Miller, Pharm.D., assistant commissioner for medical products and tobacco operations in the Office of Regulatory Affairs at the FDA. She’ll discuss the latest plans and initiatives coming out of the agency so attendees can prepare for what’s to come in FDA inspections, whether on-site or virtual.

Members of the WCG Avoca Quality Consortium (AQC) will be a constant presence in the Clinical Trials track, guiding the sessions to help participants understand:


  • Purpose-Driven Inspection Preparedness: People, Process and Technology — Critical Components to Success


This panel will connect, collaborate, and explore how building quality relationships, planning processes proactively, and using current technology solutions brings inspection success in an environment where clinical trial professionals are often doing more with less. Panelists include Téa Romero, client success manager at Clario; Neala Lane, associate director, Quality Improvement Office at Indiana University; Trevor Cole, senior manager at WCG; and Gary Shorter, senior director of emerging technology and AI at IQVIA Tech.

  • The Potential — and Limitations — of Technology-Driven TMF Compliance


TMF-readiness is and will remain a key focus for inspections and a key pain point for sponsors and CROs. Can artificial intelligence and machine learning (AI/ML) or other automation fill this gap? This discussion addresses the promise and challenges associated with applying these approaches in a validated environment. Presented by Ted Finlan, senior vice president for project planning and administration at Worldwide Clinical Trials.

  • BIMO in Action: WCG AQC Members Share Insights from Their Recent Inspection Experiences    


This session will review significant updates to the Bioresearch Monitoring Program (BIMO) / Sponsors and Contract Research Organizations Program released in September 2021 and share feedback from members’ inspection experiences. Presented by Karen Harvey, senior director of the WCG Avoca Quality Consortium.

  • And hear directly from the FDA!


Engage in a session on validating systems and equipment for compliance with the FDA’s Francisco Vicenty, program manager, Case for Quality, and Daniel Walter, policy analyst. Attendees will have the opportunity to participate in a mock inspection with Simone Pitts (invited), FDA national expert, pharmaceutical.

This level of FDA and industry expertise with this combination of must-know topics can only be found at the 17th Annual FDA Inspections Summit’s Clinical Trials track.

Conference Details

17th Annual FDA Inspections Summit

**Presented by WCG FDAnews**

Nov. 16-18, 2022 • Washington, DC

https://wcg.swoogo.com/fda-inspections-summit-2022

Tuition:

Complete Summit $1,997

Additional pricing and livestreaming options are available online.

Easy Ways to Register:

Online: https://wcg.swoogo.com/fda-inspections-summit-2022

By phone: 888-838-5578 or 703-538-7600

About WCG FDAnews:

WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations. Learn more at fdanews.com.

Share article on social media or email:

Driving Outcomes in Medical Affairs — Leveraging Technology to Identify Successful MSL-KOL Relationships, Upcoming Webinar Hosted by Xtalks


“Medical Affairs teams are critically seeking better ways to communicate their value,” says Tim Mikhelashvili, Chair, Mentorship Committee at Medical Affairs Professional Society (MAPS).

The right key opinion leader or KOL identification — with whom medical science liaisons (MSL) communicate and engage — can transform the effectiveness of the medical affairs and field medical teams. The MSL-KOL relationship can be crucial to successful patient outcomes.

“Medical Affairs teams are critically seeking better ways to communicate their value,” says Tim Mikhelashvili, Chair, Mentorship Committee at Medical Affairs Professional Society (MAPS).

“The focus of their value proposition is shifting towards patient outcomes and the patient journey through all of their activities,” Mikhelashvili explains. “As a result, the MSL (medical science liaison) value is now best expressed not only in the data they collect and communicate, but primarily in the context of the data they are able to capture and translate clinically.”

Knowing whom to approach and how to connect with them in this ever-changing landscape is central to ensuring that the team can elevate new treatments and improve patient outcomes in a real-world setting. Seeking quality engagements — those that transform the treatment paradigm — and not just quantity of engagements, will be the yardstick by which medical affairs teams are measured in the future.

Register now to learn about moving the MSL-KOL relationships from perfunctory to powerful. Join the featured speakers in reviewing the importance of KOL Identification and management and learn how to leverage the right technology and tools to create a quality engagement.

Join experts from Anju, Erick Borg, PharmD, Customer Success Manager, Medical Affairs; Steve Anzuini, Senior Solutions Engineer, Medical Affairs; and John Coritz, Senior Director, Customer Success, for the live webinar on Wednesday, November 9, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Driving Outcomes in Medical Affairs — Leveraging Technology to Identify Successful MSL-KOL Relationships.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device community. Every year, thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Cartessa Makes Foray Into Minimally Invasive Aesthetics Market With LipoAI


New LipoAI

“LipoAI delivers the energy much faster and more efficiently than previous technologies, and patients are more comfortable post-operatively. I have seen no issues with post-op numbness or hypersensitivity in the areas treated like other energy-based skin tightening devices.” – Carey Nease MD

Cartessa Aesthetics has built a reputation for identifying and marketing state-of-the-art non-invasive aesthetic technology since inception. Working closely with the leading global manufacturers, Cartessa looks for devices that offer a true benefit to providers and patients in the most high-demand treatment categories. The latest addition to their portfolio, LipoAI, represents the company’s move into the minimally invasive space. Introduced to an exclusive audience of current customers at their user forum in Scottsdale, Arizona last week, LipoAI offers a new, technologically superior, safe and minimally invasive adjunct to traditional liposuction to meet their patients’ body contouring needs. Cartessa is working closely with DEKA, the Italian manufacturer who brought the first generation of laser-assisted lipolysis (LAL) to market, to bring the newest advanced LAL technology into the aesthetic field in the form of LipoAI.

Utilizing 1444nm wavelength, the gold standard for fat and water absorption, LipoAI offers a shorter pulse duration to reach higher peak power and a higher frequency than previous generations; these advancements make LipoAI a faster, more controlled and more energy efficient device. LipoAI also boasts an exclusive AI Mode, which uses predictive algorithms to facilitate bi-communication between the provider and the device, adjusting energy delivery in real time to improve accuracy, safety and efficiency of energy distribution.

For nearly a decade, DEKA conducted extensive research in collaboration with leading Italian universities to analyze thousands of data points balancing the multiple variables such as laser energy, dosimetry, absorption coefficients and real-time temperature behavior. The result is AI Mode, a sophisticated, predictive algorithm that allows LipoAI to adapt to the provider’s technique, adjusting energy delivery intelligently and automatically.

“LipoAI delivers the energy much faster and more efficiently than previous technologies, and patients are more comfortable post-operatively,” said cosmetic surgeon Carey Nease, MD. “I have seen no issues with post-op numbness or hypersensitivity in the areas treated like other energy-based skin tightening devices.”

Cartessa is known for bringing cutting-edge technology from around the globe in every aesthetic category to the best aesthetic providers in North America. With leading products in major categories including RF microneedling, CO2, and laser hair removal, Cartessa is excited to introduce innovation in a category that marks the company’s first foray into minimally invasive procedures. The Aesthetic Society 2021 Aesthetic Plastic Surgery National Databank cites liposuction as the #1 surgical procedure performed. As a hugely popular procedure, with several limitations such as little to no skin retraction, extensive downtime, trauma to the surgeon and patient, and blood loss, LipoAI improves upon the previous generations of laser-assisted lipolysis to address a clear need in the marketplace.

“Not only is LipoAI a more powerful and intelligent device,” shared Gabe Lubin, Founder and CEO of Cartessa, “but LipoAI also produces a better patient experience: less bruising, minimal pain and less recovery time compared to other methods of liposuction, making the device a welcomed advancement for providers and their patients alike.”

LipoAI is available for U.S. providers with liposuction experience and is exclusive to Cartessa Aesthetics.

About Cartessa:

Cartessa Aesthetics is a leading North American aesthetic company focused on cutting-edge technology and industry leading customer support. Thanks to an independent business model and established relationships with top global manufacturers, Cartessa’s product portfolio offers true competitive advantages for practices and patients across every aesthetics category. Customers benefit from expertly vetted devices and end-to-end support to maximize the clinical outcomes and returns of their investment.

About DEKA M.E.L.A.

DEKA M.E.L.A. is a controlled company of the large multinational Italian group EL. EN., listed on the Star Segment of the Milan Stock Exchange (ELN.MI). The company, which has more than three decades of laser experience, chose DEKA as its company name which means attainment of perfection and excellence and is also “10” in Greek, the perfect number according to Pythagoras. The Florentine company is rooted in a culture that has made excellence of thought its dominant feature. Due to its invaluable cultural heritage and unique historical background, DEKA encompasses into its vision a promise of universal value: to turn every scientific discovery into a concrete benefit for physicians and patients, and to translate every technological innovation into ongoing improvements for the range of products and services it offers.

Share article on social media or email:

FitOn Appoints Healthcare Executive Deborah Gage to Board Of Directors


“It’s an exciting time to be in healthcare and health tech,” Gage shared. “Especially with an innovative and mission driven company like FitOn that has incredible growth metrics, a beloved consumer facing brand, and was founded by proven technology visionaries.”

FitOn, the No. 1 health & wellness platform with over 13+ million members announced the addition of Deborah Gage to their board of directors. She joins FitOn to accelerate its goal of delivering premium health and wellness care throughout the healthcare ecosystem.

“From the beginning, our goal has been to democratize digital health & wellness with a truly innovative, engaging and motivating solution that removes any barriers to entry for customers,” said Lindsay Cook, Founder & CEO of FitOn. “To deliver on our vision, we are continually expanding our technology driven solution and investing in building the best team in the world, including our board of directors. Deborah brings a wealth of experience leading innovative healthcare companies ranging from startups to Fortune 100 companies. I could not be more excited to have her join us as we continue transforming the healthcare system to improve access, consumer experiences and health outcomes.”

Deborah Gage is joining FitOn’s Board of Directors, which also includes David Schaller from Delta-v Capital, Yash Patel from Telstra Ventures and FitOn’s executive team.

Deborah is active as a limited partner of several funds and as an advisor to PE and Venture firms. In her most recent CEO role, Deborah was President and Chief Executive of Medecision from 2011 to 2021, where she led the turn-around and profitable growth of the company to over $100M, establishing the Company’s mission and market leading position as a digital transformation partner in care management and consumer engagement.

Before joining Medecision, Deborah was an early team member at the health industry’s leading analytics firm Truven Healthcare (then NASDAQ: MDST). She then served as CEO of several private equity and venture-backed Saas focused Healthcare firms which included SolutionPoint®, Inc., GTESS Corporation, and RosettaMed (acquired by Kryptiq).

“As an active entrepreneur and operator focused on improving healthcare access, I’ve seen just how much opportunity exists to improve the user experience and to impact health outcomes,” Gage said. “I have a passion for working with companies that are transforming their industries. With millions of active members on their platform, what FitOn has already accomplished is impressive and I believe it represents a model to deliver accessible and enjoyable healthcare solutions at a scale few other companies have achieved.”

“It’s an exciting time to be in healthcare and health tech,” Gage shared. “Especially with an innovative and mission driven company like FitOn that has incredible growth metrics, a beloved consumer facing brand, and was founded by proven technology visionaries.”

ABOUT FITON:

FitOn is the largest health & wellness platform providing instant access to the widest variety of premium workouts and health experiences, all from world class trainers, experts and celebrities. It works with top health plans and enterprise customers to drive best-in-class engagement through its digital platform, expansive network of fitness studios and gyms, and condition management courses. The FitOn Health platform provides the only truly integrated hybrid preventative care solution for employers and health plans to supercharge their benefits and help their members be more active, connect with coworkers, friends and family, and make leading a healthy lifestyle fun and motivating. FitOn members have shown their passion for the product by completing more than 1 billion workout minutes and leaving 400,000+ 5-Star reviews. Learn more at: https://health.fitonapp.com

For more information, please contact: press@fitonapp.com

Share article on social media or email:

Targeting One Type of Immune Cell With Another Slows Cancer Growth in Preclinical Studies


Mice with lung cancer were treated with macrophage-targeting CAR T cells resulting in reduced numbers of tumor macrophages (right side), shrunken tumors, and extended survival.

“Our initial goal was just to use the CAR T cells to kill the immunosuppressive macrophages, but we discovered they were also boosting tumor immunity by releasing this powerful immune-boosting molecule,” – Brian Brown, PhD

A new approach to cancer immunotherapy that uses one type of immune cell to kill another—rather than directly attacking the cancer—provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York. The findings were published October 11, 2022 in the journal Cancer Immunology Research [https://doi.org/10.1158/2326-6066.CIR-21-1075 .

The study involved a twist on a type of therapy that uses immune cells known as CAR T cells. CAR T cells in current clinical use are engineered to recognize cancer cells directly and have successfully treated several blood cancers. But there have been challenges that prevent their effective use in many solid tumors.

Most solid tumors are heavily infiltrated by a different type of immune cell called macrophages. Macrophages help tumors grow by blocking the entry of T cells into tumor tissue, which prevents CAR T cells and the patient’s own T cells from destroying the cancer cells.

To tackle this immune suppression at the source, the researchers engineered T cells to make a “chimeric antigen receptor” (CAR) that recognizes a molecule on the surface of macrophages. When these CAR T cells encountered a tumor macrophage, the CAR T cell became activated and killed the tumor macrophage.

Treatment of mice bearing ovarian, lung, and pancreatic tumors with these macrophage-targeting CAR T cells reduced the number of tumor macrophages, shrunk the tumors, and extended their survival.

The killing of tumor macrophages allowed the mouse’s own T cells to access and kill the cancer cells. The investigators further demonstrated that this anti-tumor immunity was driven by release of the cytokine interferon-gamma—a molecule involved in the regulation of inflammatory responses—from the CAR T cells.

“Our initial goal was just to use the CAR T cells to kill the immunosuppressive macrophages, but we discovered they were also boosting tumor immunity by releasing this powerful immune-boosting molecule,” said senior author Brian Brown, PhD, Director of the Icahn Genomics Institute and Associate Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at Icahn Mount Sinai. “It was a one-two punch from this single treatment.”

Shifting the sights of CARs from cancer cells to tumor macrophages potentially addresses another key barrier to the successful elimination of solid tumors with CAR T cells. There are very few proteins found exclusively on cancer cells and not on healthy tissues that can be used to target cancer cells in solid tumors directly without damaging the healthy tissue.

The macrophages found in tumors that suppress immunity are very similar across different types of cancer and very different from macrophages in healthy tissues.

This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed to date have had limited success in clinical trials.

“Our molecular studies of human tumors have revealed macrophage subsets present in human tumors and not in normal tissues and are similar across tumors and across patients. So macrophage-targeting CAR T cells could be a broad way to target different types of solid tumors and improve immunotherapy,” said Miriam Merad, MD, PhD, co-senior author of the study, and Director of PrIISM.

Next, the researchers are working on tumor macrophage-specific CAR and generating humanized versions of the genetic instructions, so that they can be introduced into cancer patients’ own T cells.

The paper is titled, “Targeting macrophages with CAR T cells delays solid tumor progression and enhances anti-tumor immunity.”

Additional co-authors are Alfonso R. Sánchez-Paulete, PhD, Jaime Mateus-Tique, Gurkan Mollaoglu, PhD, , Sebastian R. Nielsen, PhD, Adam Marks, Ashwitha Lakshmi, Jalal A. Khan, MD, PhD, C. Matthias Wilk, MD, Luisanna Pia, Alessia Baccarini, PhD, all from Icahn Mount Sinai.

B.D.B. was supported by NIH (R01CA257195) and a grant from the Alliance for Cancer Gene Therapy. M.M. was supported by NIH (R01CA254104). A grant from the Applebaum Foundation also supported the project. A.R.S.P. was supported by a grant from Fundación Alfonso Martín Escudero (Spain).

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the eight- member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked 14th nationwide in National Institutes of Health (NIH) funding and among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 35 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, as well as gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and Master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,000 clinical residents and fellows training throughout the Health System. In addition, more than 550 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into healthcare products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs.

Through the Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.